GSK enters agreement to acquire RAPT Therapeutics GSK plc (LSE NYSE: GSK) today announced that it has entered a definitive agreement to acquire RAPT Therapeutics (“RAPT”) (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE
RAPT Therapeutics Announces $150 Million Private Placement RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant unmet needs in inflammatory diseases
PowerPoint Presentation ABSTRACT BACKGROUND: FLX475 (tivumecirnon, or TIVU) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment The FLX475-02 trial (NCT03674567) is a phase 1 2 study of FLX475 as monotherapy and in combination with pembrolizumab in subjects with advanced cancer Early encouraging data on the biologic effects
SEC Filings | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
RAPT Therapeutics Reports Second Quarter 2024 Financial Results About RAPT Therapeutics, Inc RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology
A combined mregDC and Treg signature associates . . . - RAPT Therapeutics We thank our colleagues at RAPT Therapeutics and scientific advisors for helpful suggestions and discussion This study is in collaboration with Merck Sharp Dohme LLC, a subsidiary of Merck Co , Inc , Rahway, NJ, USA st Spatial profiling was performed (n=2, tumors) with a multicolor IF panel on FFPE tumors